Sepracor Looking To Estorra DTC Ads To Wake Up Insomnia Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sepracor plans to spend $60 mil. on direct-to-consumer advertising for its insomnia agent Estorra in its first year on the market.
You may also be interested in...
Indiplon NDA Expected Mid-Year; Neurocrine Reports Positive Long-Term Data
Neurocrine Biosciences and Pfizer expect to submit NDAs for immediate- and modified-release formulations of their sleep agent indiplon by June.